Abstract
Burkitt lymphoma is the most common AIDS-related lymphoma (ARL) in childhood. The major issues in adult and pediatric ARL include identifying the optimal chemotherapy regimen and the concurrent treatment of both rituximab and highly active anti-retroviral therapy (HAART). We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy. The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/AIDS patients with Burkitt lymphoma.
(c) 2008 Wiley-Liss, Inc.
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Acquired Immunodeficiency Syndrome / physiopathology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiretroviral Therapy, Highly Active
-
Burkitt Lymphoma / drug therapy*
-
Burkitt Lymphoma / pathology
-
Burkitt Lymphoma / virology
-
Child
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lymphoma, AIDS-Related / drug therapy*
-
Lymphoma, AIDS-Related / pathology
-
Lymphoma, AIDS-Related / virology
-
Prednisone / therapeutic use
-
Rituximab
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone